Company intelligence / Profile preview
Mirae Cell Bio
Seoul, South Korea
- Ownership
- Private
- Development stage
- Other
01
Overview
Mirae Cell Bio's lead program MR-MC-01 is in phase 1/2 trials for interstitial cystitis and underactive bladder. Clinical trials are ongoing; the therapy is a first-in-class designated orphan drug in Korea and based on allogeneic embryonic stem cell-derived mesenchymal stem cells. The company also explores stem cell and exosome-based programs for neurodegenerative disorders using proprietary platforms with transgenic pig models for Alzheimer's efficacy testing[1][2][3][4][5].
- Therapeutic areas
- UrologyNeurologyNephrology
- Modalities
- Cell therapyStem cell therapyMesenchymal stem cell therapyExosome-based therapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Asan Medical CenterJeonnam Bio Foundation
Beyond the preview
Go deeper on Mirae Cell Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mirae Cell Bio.